Necrosulfonamide is primarily used as a selective inhibitor of necroptosis, a form of regulated cell death. It specifically targets and inhibits MLKL (mixed lineage kinase domain-like protein), which plays a crucial role in the execution phase of necroptotic signaling. This makes it a valuable tool in research settings for studying cell death pathways, particularly in distinguishing necroptosis from other forms of cell death like apoptosis or autophagy. It is widely applied in studies related to inflammatory diseases, neurodegenerative disorders, and ischemic injuries, where uncontrolled necroptosis contributes to tissue damage. Researchers use necrosulfonamide to probe the involvement of MLKL in disease models, helping to validate therapeutic targets. Additionally, it has been employed in cancer research to investigate how blocking necroptosis influences tumor survival and response to treatments. Its application enables a deeper understanding of cellular mechanisms and supports the development of targeted therapies.